GSA Capital Partners LLP Sells 40,102 Shares of Abbott Laboratories $ABT

GSA Capital Partners LLP cut its holdings in Abbott Laboratories (NYSE:ABT) by 90.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,477 shares of the healthcare product maker’s stock after selling 40,102 shares during the quarter. GSA Capital Partners LLP’s holdings in Abbott Laboratories were worth $406,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of ABT. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories during the 4th quarter valued at about $25,000. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories during the 4th quarter worth $25,000. Purpose Unlimited Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter worth $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $26,000. Finally, Abound Financial LLC bought a new position in shares of Abbott Laboratories in the 4th quarter valued at about $26,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first U.S. wearable designed to continuously monitor both glucose and ketone levels. The device is intended to help detect rising ketones associated with diabetic ketoacidosis and integrates with Abbott’s Libre app, digital-health ecosystem and compatible automated insulin-delivery systems. The approval strengthens Abbott’s continuous glucose-monitoring franchise and could expand its addressable market. Reuters FDA authorization article
• Positive Sentiment: TD Cowen raised its price target for ABT from $115 to $135 and maintained a “buy” rating, implying approximately 18% upside from the referenced $114.11 level. The target increase reflects confidence in Abbott’s growth prospects and valuation relative to peers. Benzinga analyst price target report
• Neutral Sentiment: Industry forecasts identify Abbott as a participant in expanding atrial-fibrillation treatment and device markets, particularly pulsed-field ablation, mapping catheters and left-atrial-appendage closure. These reports point to long-term opportunity but do not provide new Abbott-specific financial guidance. Atrial fibrillation treatment devices market report
• Negative Sentiment: Abbott agreed to pay $670 million to settle claims that its specialized premature-infant formula contributed to necrotizing enterocolitis. The settlement removes some litigation uncertainty but highlights continuing legal and financial risks. Abbott formula claims settlement article

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $114.11 on Thursday. The stock has a market capitalization of $197.45 billion, a price-to-earnings ratio of 36.93, a PEG ratio of 2.25 and a beta of 0.59. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The stock’s 50 day moving average price is $101.66 and its two-hundred day moving average price is $100.13.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. Abbott Laboratories’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. TD Cowen increased their price target on shares of Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday. BTIG Research upped their target price on Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research report on Friday, July 17th. JPMorgan Chase & Co. boosted their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Royal Bank Of Canada restated an “outperform” rating and set a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, Wells Fargo & Company lifted their price target on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.